LEADER 04202nam 22006375 450 001 9910640388903321 005 20260210140935.0 010 $a981-19-5558-1 024 7 $a10.1007/978-981-19-5558-7 035 $a(MiAaPQ)EBC7175155 035 $a(Au-PeEL)EBL7175155 035 $a(CKB)25994481200041 035 $a(DE-He213)978-981-19-5558-7 035 $a(PPN)267811217 035 $a(EXLCZ)9925994481200041 100 $a20230108d2022 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHormone Related Cancer Mechanistic and Nanomedicines $eChallenges and Prospects /$fedited by Mahfoozur Rahman, Waleed H Almalki, Majed Alrobaian, Sarwar Beg, Khalid S Alharbi 205 $a1st ed. 2022. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2022. 215 $a1 online resource (355 pages) 311 08$aPrint version: Rahman, Mahfoozur Hormone Related Cancer Mechanistic and Nanomedicines Singapore : Springer,c2023 9789811955570 327 $aChapter 1. Conventional Treatment Approaches in Hormonal Cancer Treatment and Challenges -- Chapter 2. Concept of Nanomedicine in Endocrine Hormone Cancer Treatment -- Chapter 3. Progress of Cancer Nanomedicine, Clinical Hurdles and Opportunities -- Chapter 4. Emergence of Nanohybrids in Hormonal Cancer Targeted Therapy -- Chapter 5. Conventional to Nanoscale-Based Carrier System in Management of Ovarian Cancer -- Chapter 6. Pancreatic Cancer Nanoparticles Targeted Therapy via Epidermal Growth Factor Receptor -- Chapter 7. Nanocarriers Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead -- Chapter 8. Pancreatic Cancer Treatment by Using of Theranostics Nanoparticles -- Chapter 9. Nanomedicine Based Combinational Therapy for Breast Cancer -- Chapter 10. Nano-Liposomal System for Breast Cancer Therapy -- Chapter 11. Conventional to Nanotherapeutic Strategies against Triple-Negative Breast Cancer -- Chapter 12. Effect of Thymoquinone and Its Delivery Through Using of Nanomedicine inBenign Prostatic Hyperplasia -- Chapter 13. Concept of Nanotechnology in Management of Neuroendocrine Tumours -- Chapter 14. Neurocognitive Underpinning of Neurological Disorders: The Role of Default Mode Network -- Chapter 15. Neuroendocrine Carcinoma of The Endometrium: Conventional Treatment Approach to Nanomedicine -- Chapter 16. Effective Luteinizing Hormone Drug Delivery by Gold Nanoparticles in Hormonal Cancer Treatment -- Chapter 17. Regulatory Landscapes in Approval of Cancer Vaccines. 330 $aThe nanotheranostics sector provides a very promising strategy for monitoring drug biodistribution and pathology longitudinal processes by integrating the imaging and drug delivery functions in one single nanoformulation, providing vital insights into the identification of tumour and predicting the efficacy of nanomedicine. For its unique properties, which include their small size and biocompatibility and ability to permeate the cellular membrane with carrying drugs, nanomaterials have been used for various biomedical applications. This book covers the progress made in hormone-related cancer and their management by nonmedicinal therapy for targeting the hormone regulated cancer with their clinical progress and clinical hurdles. 606 $aOncology 606 $aHormones 606 $aCancer 606 $aOncology 606 $aHormone 606 $aCancers 606 $aCāncer$2thub 606 $aMalalties de les glāndules endocrines$2thub 606 $aNanomedicina$2thub 608 $aLlibres electrōnics$2thub 615 0$aOncology. 615 0$aHormones. 615 0$aCancer. 615 14$aOncology. 615 24$aHormone. 615 24$aCancers. 615 7$aCāncer 615 7$aMalalties de les glāndules endocrines 615 7$aNanomedicina 676 $a616.994071 702 $aRahman$b Mahfoozur 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910640388903321 996 $aHormone Related Cancer Mechanistic and Nanomedicines$93269298 997 $aUNINA